The angioedema treatment market comprises drugs used for treatment of edema that occurs below the skin or mucous membranes. Angioedema is a clinical condition characterized by acute localized swelling of deep dermis, subcutaneous, or submucosal tissues. It causes swelling of the hands, feet, arms, legs, face, airway and intestinal tract. The increasing prevalence of hereditary angioedema (HAE) acts as a major driver for angioedema treatment market growth. HAE is a genetic disorder in which C1 inhibitor protein either doesn’t work or isn’t present in enough quantities in the blood. Key symptoms of HAE include abdominal pain, swelling in the face, throat, and airway. Untreated attacks can prove fatal if swelling blocks the airway.
The global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. Bayer AG’s Berinert and CSL Behring’s Ruconest are leading plasma-derived C1 esterase inhibitor therapies used for prophylaxis and treatment of HAE attacks. Monoclonal antibody therapies like Takeda’s Takhzyro are gaining popularity. Growing adoption of long-acting prophylactic therapies for preventing HAE attacks is a major factor boosting market revenues.
The prevalence of HAE is estimated to affect 1 in 10,000 to 1 in 50,000 people globally. With increasing disease diagnosis, demand for angioedema therapies is rising steadily. Moreover, growing awareness about early treatment and prevention of HAE attacks to avoid mortality is further fueling the adoption of prophylactic therapies.
Technological advancements have led to development of novel drug delivery systems like subcutaneous injections and intravenous infusions for long-acting prevention of angioedema attacks. This has improved patient adherence to treatment regimens compared to frequent injections.
Market Trends
Outpatient care trend – Growing preference for self-administered angioedema therapies at home settings is increasing demand for user-friendly drug delivery systems like prefilled syringes and auto-injectors. This trend is driven by the need for avoiding ER visits and hospital admissions.
Pipeline therapies – A strong pipeline with novel drug entities in various clinical trial phases will further expand treatment options. Some trends include subcutaneously administered small molecule candidates and monoclonal antibodies. This healthy pipeline supports market growth over the forecast period.
Market Opportunities
Emerging markets – There is high unmet need in developing countries owing to lack of diagnosis and inadequate healthcare infrastructure. Initiatives to spread awareness can boost diagnosis rates and accessibility to therapies in emerging markets of Asia Pacific and Latin America.
Orphan drug status – Regulatory incentives like orphan drug designation accelerate drug development and market exclusivity. Companies are actively exploring genetic disorders like HAE for new treatment opportunities.
Impact of COVID-19 on Angioedema Treatment Market Growth
The COVID-19 pandemic impacted the angioedema treatment market notably. Hospital access restrictions and priority focus on COVID care hindered treatment of angioedema patients. Travel barriers disrupted diagnosis and routine blood monitoring for HAE patients relying on specialty care. Telemedicine partially addressed such issues, helping physicians remotely monitor and counsel patients. However, virtual consultations could not replace in-person therapies like IV Plasma-Derived C1 Esterase Inhibitor or vaccination.
Supply chain disruptions impacted drug manufacturing and distribution. Social distancing measures led to canceled or deferred elective medical procedures. This reduced patient loads and adversely impacted revenue streams for providers and pharma companies. Economic uncertainties made patients reluctant toward expensive long-term treatments. Stockpiling of medications by anxious consumers in initial outbreak months increased shortages.
With vaccination drives progressing globally, market recovery is seen from 2021 onwards. Treatment priorities are being restored and clinical trials resumed. Telehealth is here to stay as a complementary approach. Pharma companies are innovative to ensure undisrupted supplies. Overall growth is projected though near-term setbacks are acknowledged. Continuous research into new therapies holds promise to overcome future public health crises.
Angioedema Treatment Markets by Geography
In terms of value, North America holds the largest share of the angioedema treatment market currently. This is attributed to high per capita healthcare spends, rising healthcare awareness, strong reimbursement frameworks and presence of major market players.
The Asia Pacific region is poised for fastest growth in the forecast period owing to its huge patient pool, increasing healthcare access and expanding medical tourism industry. Rising chronic disease burden, growing middle class and government initiatives are driving the regional market upward. Pharma companies are actively partnering local players to tap into high potential Asian economies like China and India.
